Chen, Guo-Feng <br/><br/>
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.  [electronic resource] 

 -  PloS one  2016 
 - e0155934 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0155934  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Asian People<br/>Benzimidazoles--administration & dosage<br/>China--epidemiology<br/>Costs and Cost Analysis<br/>Female<br/>Fluorenes--administration & dosage<br/>Hepacivirus<br/>Hepatitis C--drug therapy<br/>Humans<br/>Male<br/>Markov Chains<br/>Models, Economic<br/>Sofosbuvir--administration & dosage